Home > Neurology > MS Virtual 2020

MS Virtual 2020


8th Joint ACTRIMS and ECTRIMS Meeting 11-13 September 2020

Table of Contents



Letter from the Editor

Editor
Prof. Hans-Peter Hartung, Heinrich-Heine-University, Germany

MS Virtual 2020 Highlights Podcast

Presented By
Michiel Tent, Medicom

COVID-19 and MS

Risk of COVID-19 not increased in MS patients

Age and EDSS are risk factors for severe COVID-19

Anti-CD20 DMTs associated with worse COVID-19 outcomes

Black MS patients have poorer COVID-19 outcomes

Biomarkers

Gut bacteria associated with relapse in paediatric-onset MS

Predictive value of CSF Aβ and tau proteins in MS

Serum NfL as biomarker for suboptimal treatment response

Interrupting DMT due to pregnancy increases NfL levels

Predicting autoimmunity in patients treated with alemtuzumab

Serum glial fibrillary acidic protein predicts relapses in NMOSD

Assessing demyelination using myelin water imaging

Grey matter network measures predict disability and cognition

Lesion-specific perfusion levels affect myelin loss and repair

Treatment Strategies and Results

Management of progressive MS with approved DMT

Presented By
Prof. Xavier Montalban, Vall d'Hebron University Hospital, Spain

Outcomes in patients on alemtuzumab with thyroid adverse events

Safety and efficacy of dimethyl fumarate: 13 years of follow-up

Update on estimated PML risk related to fingolimod

Less thalamic atrophy in patients initiating ocrelizumab earlier

No new safety signals in ofatumumab open-label data

Long-term safety and efficacy of ozanimod in RMS

Low-dose rituximab as effective as high-dose, but safer

TERIKIDS trial extension of teriflunomide in paediatric MS

Teriflunomide improves satisfaction versus prior DMT regardless of age

Safety and efficacy of cladribine, glatiramer acetate, and more

Novel Treatment Directions

Functional potential of gut microbiome in paediatric MS

Modulating BTK-dependent inflammatory signalling in microglia

Therapeutic potential of anti-MOSPD2 monoclonal antibodies

Masitinib: a first-in-class TKI as treatment of progressive MS

Gold nanocrystals may improve brain metabolic profile

Retinoid-X receptor agonist promotes remyelination

Neuromyelitis Optica Spectrum Disorders

Gut dysbiosis in NMOSD promotes CNS autoimmunity

NG-specific biomarkers differentiate NMOSD from MS

Eculizumab reduces long-term relapse risk in AQP4-positive NMOSD

Satralizumab lowers risk of severe relapse in NMOSD patients

Clinical features of a recently identified disease: GFAP autoimmunity

Miscellaneous Topics

Gender-based approach to MS therapeutics: a missed opportunity

Disease activity during pregnancy in a modern MS cohort

Cardiovascular risk factors may contribute to brain atrophy in MS patients

Amantadine, modafinil, and methylphenidate for MS-related fatigue

site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com